 Home > Biochemistry News > Biotechnology News > Acquired 4 targeted therapies including TIGIT antibody and Gilead to expand its oncology pipeline for US$725 million

Acquired 4 targeted therapies including TIGIT antibody and Gilead to expand its oncology pipeline for US$725 million

 Last Update: 2021-12-02
 Source: Internet
 Author: User

Tags

what adenosine triphosphate

reference standard

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Today, Gilead Sciences and Arcus Biosciences jointly announced that Gilead has exercised its option to obtain multiple R&D projects in Arcus’ clinical R&D pipeline, including two monoclonal antibodies domvanalimab and AB308 that target TIGIT, and small Molecular therapy etrumadenant and quemliclustat

Gilead and Arcus reached a 10-year partnership in May last year to jointly develop drugs under development in Arcus' R&D pipeline

▲The mechanism by which TIGIT regulates the immune response of T cells (picture source: reference [1])

Domvanalimab (AB154) is an anti-TIGIT antibody that removes the Fc-terminal function of the antibody.

▲Introduction of Domvanalimab and AB308 (picture source: Arcus official website)

Etrumadenant is an adenosine A2a/A2b dual receptor antagonist for the treatment of NSCLC, colon cancer and prostate cancer.

Image source: Arcus official website

Quemliclustat is a small molecule CD73 inhibitor for the treatment of metastatic pancreatic ductal adenocarcinoma (PDAC) and is in phase 1 clinical trials

By obtaining these clinical development projects, Gilead and Arcus can accelerate the clinical development of drugs and promote the exploration of combination therapies

According to the agreement between the two parties, Arcus will receive a total of US$725 million in payments

Reference materials:

[1] Gilead Exercises Options to Three Arcus Biosciences Clinical-Stage Programs and Adds Research Collaboration.

[2] ASCO 20 Roche Analyst Event.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.